These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25792732)

  • 1. PARtitioning protease signaling.
    Nieman MT
    Blood; 2015 Mar; 125(12):1853-5. PubMed ID: 25792732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.
    Aisiku O; Peters CG; De Ceunynck K; Ghosh CC; Dilks JR; Fustolo-Gunnink SF; Huang M; Dockendorff C; Parikh SM; Flaumenhaft R
    Blood; 2015 Mar; 125(12):1976-85. PubMed ID: 25587041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
    Gandhi DM; Majewski MW; Rosas R; Kentala K; Foster TJ; Greve E; Dockendorff C
    Bioorg Med Chem; 2018 May; 26(9):2514-2529. PubMed ID: 29685684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia.
    Schoergenhofer C; Schwameis M; Gelbenegger G; Buchtele N; Thaler B; Mussbacher M; Schabbauer G; Wojta J; Jilma-Stohlawetz P; Jilma B
    Thromb Haemost; 2018 Jul; 118(7):1176-1184. PubMed ID: 29864779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.
    Falcone GJ; Brouwers HB; Rosand J
    Stroke; 2012 Dec; 43(12):3158-9. PubMed ID: 23160886
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting PAR1: Now What?
    Flaumenhaft R; De Ceunynck K
    Trends Pharmacol Sci; 2017 Aug; 38(8):701-716. PubMed ID: 28558960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury.
    De Ceunynck K; Peters CG; Jain A; Higgins SJ; Aisiku O; Fitch-Tewfik JL; Chaudhry SA; Dockendorff C; Parikh SM; Ingber DE; Flaumenhaft R
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E982-E991. PubMed ID: 29343648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorapaxar (Zontivity) for prevention of thrombotic cardiovascular events.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):85-6. PubMed ID: 25211301
    [No Abstract]   [Full Text] [Related]  

  • 10. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.
    Lee M; Saver JL; Hong KS; Wu HC; Ovbiagele B
    Stroke; 2012 Dec; 43(12):3189-95. PubMed ID: 23160882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
    Oestreich J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
    Macaulay TE; Allen C; Ziada KM
    Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
    Tricoci P; Neely M; Whitley MJ; Edelstein LC; Simon LM; Shaw C; Fortina P; Moliterno DJ; Armstrong PW; Aylward P; White H; Van de Werf F; Jennings LK; Wallentin L; Held C; Harrington RA; Mahaffey KW; Bray PF
    Blood Cells Mol Dis; 2018 Sep; 72():37-43. PubMed ID: 30055940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
    Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
    Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
    Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
    J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
    Ahn HS; Chackalamannil S; Boykow G; Graziano MP; Foster C
    Curr Pharm Des; 2003; 9(28):2349-65. PubMed ID: 14529396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting biased signaling by PAR1: function and molecular mechanism of parmodulins.
    Künze G; Isermann B
    Blood; 2023 Jun; 141(22):2675-2684. PubMed ID: 36952648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease-activated receptor-1 antagonists: focus on SCH 530348.
    Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
    Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.